In 2003, the first anti-tumor gene therapy drug recombinant human p53 adenovirus (rAd-p53), trade name Gendicine, was approved by China Food and Drug Administration (CFDA) for the combined radiotherapy of head and neck squamous cell carcinoma [51, 52]. Here, TP53 is linked to neoplasm.